Akebia Therapeutics, Inc.

AKBA

$0.95

-3.31%

N/A-$0.03

Healthcare

Biotechnology

NASDAQ

Active Trading

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for ...

Fundamental Analysis of AKBA

Loading analysis...

Profitability

Net Margin-13.54%

Operating Margin-6.91%

Valuation

P/E Ratio-9.10x

Current Ratio1.43

Efficiency

ROE-93.74%

ROA-8.48%

Fundamental Analysis of AKBA

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

Key Strengths of AKBA

Industry-leading gross margins
Strong cash flow generation
High R&D investment ratio
Market leadership in AI chips

Risk Factors of AKBA

Premium valuation multiples
Semiconductor cycle exposure
Intense competition
Geographic concentration

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$255.06M

-9.1x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin79.48%

Net Profit Margin-13.54%

Debt/Equity Ratio2.16

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of AKBA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of AKBA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	-18.13%	—	—	Flat
Operating Margin	—	-12.88%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of AKBA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	1.427	—	—	Flat
Quick Ratio	—	1.346	—	—	Flat
Debt / Equity	—	2.157	—	—	Flat

Valuation of AKBA

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-9.50x	—	—	Flat
P/B	—	12.29x	—	—	Flat

Supply Chain of AKBA

RELATIONS

Upstream

Patheon Manufacturing Services LLC (Thermo Fisher Scientific)NYSE:TMOSiegfried Evionnaz SA (Siegfried Holding AG)SIX:SFZNSTA Pharmaceutical Hong Kong Limited (WuXi AppTec / WuXi STA)HKEx:2359 Patheon Inc. (Thermo Fisher Scientific — Ontario site)NYSE:TMO

Downstream

U.S. Renal Care (USRC)DaVita Inc.NYSE:DVA Fresenius Medical Care AG & Co. KGaANYSE:FMS McKesson CorporationNYSE:MCK Cencora, Inc. (formerly AmerisourceBergen)NYSE:COR Cardinal Health, Inc.NYSE:CAH Fresenius Medical Care RxNYSE:FMSMitsubishi Tanabe Pharma Corporation (MTPC)TSE:4508Panion & BF Biotech, Inc.TWSE:1760Cyclerion Therapeutics, Inc.NASDAQ:CYCN Viatris Inc. (formerly Mylan)NASDAQ:VTRSCSL Vifor (CSL Limited)ASX:CSL

Proxies

FibroGen, Inc.NASDAQ:FGEN GSK plcNYSE:GSK Ardelyx, Inc.NASDAQ:ARDX Unicycive Therapeutics, Inc.NASDAQ:UNCY

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer